Alpha Cognition Inc. is a commercial stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s disease and Cognitive Impairment with mild Traumatic Brain Injury (mTBI). The Company's ZUNVEYL (benzgalantamine) product is a delayed release oral tablet formulation indicated for the treatment of mild to moderate dementia of the Alzheimer’s type in adults. Its pre-clinical development programs include ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer’s disease; ALPHA-1062 sublingual formulation; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mTBI; ALPHA-0602; ALPHA-0702 & ALPHA-0802 (Progranulin and Progranulin GEM’s) for the treatment of neurodegenerative diseases including amyotrophic lateral sclerosis or Lou Gehrig’s disease and spinal muscular atrophy, and ALPHA-1062 for the treatment of acute pancreatitis.
企業コードACOG
会社名Alpha Cognition Inc
上場日Jun 09, 2021
最高経営責任者「CEO」Mcfadden (Michael E)
従業員数52
証券種類Ordinary Share
決算期末Jun 09
本社所在地c/o 1200 - 750 West Pender Street
都市VANCOUVER
証券取引所NASDAQ OMX - NASDAQ BASIC
国Canada
郵便番号V6C 2T8
電話番号16045649244
ウェブサイトhttps://www.alphacognition.com/
企業コードACOG
上場日Jun 09, 2021
最高経営責任者「CEO」Mcfadden (Michael E)
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし